Latest News RSS

December 8, 2016 Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease

December 8, 2016Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study ofNovel Treatment Paradigm for Pompe DiseaseATB200/AT2221 Safety Data Show No Infusion-Associated Reactions Following 100+ Infusions Clinical Pharmacokinetic (PK) Profile as Predicted Based on Previously Reported Preclinical Data Biomarkers of Muscle Damage are Generally Stable or Trending Towards Improvement...

Read more →

Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease

  PRESS RELEASE Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4, 2016 - Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a...

Read more →

10-17-2014 UPDATE

10-14

Read more →

Upcoming Meetings/Events

Coming Soon.

 

 

 

 

 

 

 

 

 

 

 

 

Medical Alert Brochure